Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study
Authors:
- 6 May 2011
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 27 (4) , 348-353
Abstract
Background: Because pharmacotherapies in type 2 diabetes exert complex effects, we examined the different anti‐diabetic strategies, especially the influence of insulin doses, on the activation of oxidative stress, a key player in atherosclerosis, ageing and the risk of cancer.Methods: This observational study included 122 persons with type 2 diabetes, 61 treated with oral hypoglycaemic agents alone (group I), 61 treated with a combination of oral hypoglycaemic agents and insulin at either a low dose (n = 30) or high dose (≥0.40 unit/kg/day, group IIb, n = 31) of insulin. Oxidative stress was estimated from 24‐h urinary excretion rates of 8‐iso‐prostaglandin F2α. Haemoglobin A$_{\rm{1c}}$ (%) was also measured to assess overall diabetic control.Results: The 24‐h excretion rates of 8‐iso‐prostaglandin F2α [median (range) pmol/mmol of creatinine] were much lower in group IIa [68 (32–220)] than in either group I [120 (26–329) p < 0.001] or group IIb [101 (30–289) p = 0.026]. Considering groups IIa and IIb as a whole, a significant and positive relationship (p = 0.021) was observed between insulin dose and 8‐iso‐prostaglandin F2α. Haemoglobin A$_{\rm{1c}}$ was comparable in the three groups.Conclusions: The main benefit of insulin therapy is the restoration and maintenance of near normal glycaemia. However insulin at elevated doses can promote oxidative stress which is thought to be an important mediator of some of the deleterious effects of insulin. Our study shows that the link between insulin action and oxidative stress in type 2 diabetes is complex and warrants further study. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 24 references indexed in Scilit:
- Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic PatientsDiabetes Care, 2010
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- DNA Damage, Aging, and CancerNew England Journal of Medicine, 2009
- The influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia, 2009
- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort studyDiabetologia, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral AgentsDiabetes Care, 2008
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998